Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: Results from the Acute Coronary Syndrome Israeli Survey (ACSIS)

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Leibovitz, Eyal ^a,d   Gottlieb, Shmuel ^b,c,d   Goldenberg, Ilan ^b,d   Gevrielov Yusim, Natalie ^b   Matetzky, Shlomi ^b,c   Gavish, Dov ^a,d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Acute coronary syndrome; Diabetes mellitus; DPP4 inhibitors; Sitagliptin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; ANTIDIABETIC AGENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HEALTH SURVEY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; ISRAEL; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREMEDICATION; RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; COMPLICATION; DIABETES MELLITUS, TYPE 2; LENGTH OF STAY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LENGTH OF STAY; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRAZINES; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TREATMENT OUTCOME; TRIAZOLES;

EID: 84875355062     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-53     Document Type: Article

References (29)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14. 10.1016/j.diabres.2009.10.007, 19896746.
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. American heart association; American diabetes association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American heart association and the American diabetes association. Circulation 2007, 115:114-126.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761, 17517853.
4. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and drug administration. N Engl J Med 2010, 363:1489-1491. 10.1056/NEJMp1010788, 20942663.
5. Kim JY, Lim DM, Moon CI, Jo KJ, Lee SK, Baik HW, Lee KH, Lee KW, Park KY, Kim BJ. Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity. J Korean Med Sci 2010, 25:1626-1632. 10.3346/jkms.2010.25.11.1626, 2967000, 21060752.
6. Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007, 27:1163-1180. 10.1592/phco.27.8.1163, 17655515.
7. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571. 10.1007/s00125-006-0416-z, 17001471.
8. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatorydisease?. Trends Pharmacol Sci 2009, 30(11):600-607. 10.1016/j.tips.2009.08.003, 19837468.
9. Arbelle JE, Porath A, Cohen E, Gilutz H, Garty M. Israeli National Survey Group on Acute Myocardial Infarction, 2000. Triage disposition of patients with acute myocardial infarction-ACSIS 2000. Isr Med Assoc J 2003, 5:786-790.
10. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967, 20:457-464. 10.1016/0002-9149(67)90023-9, 6059183.
11. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011, 28:1176-1181. 10.1111/j.1464-5491.2011.03331.x, 21923696.
12. Chen X. Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8. Adv Exp Med Biol 2006, 575:27-32. 10.1007/0-387-32824-6_3, 16700505.
13. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008, 51:1637-1642. 10.1161/HYPERTENSIONAHA.108.112532, 2396195, 18443229.
14. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with the metabolic syndrome. Clin Exp Pharmacol Physiol 2010, 37:689-9. 10.1111/j.1440-1681.2010.05389.x, 3069484, 20374254.
15. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139-153. 10.1016/j.clinthera.2007.01.015, 17379054.
16. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, . DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. 10.1016/S0140-6736(08)61206-4, 18782641, DURATION-1 Study Group.
17. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. LEAD-3 (mono) study group. Liraglutide versus glimepiride Monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481. 10.1016/S0140-6736(08)61246-5, 18819705.
18. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151. 10.2337/diabetes.54.1.146, 15616022.
19. Müssig K, Oncü A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Häring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102:646-647. 10.1016/j.amjcard.2008.06.029, 18721530.
20. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598. 10.1177/0091270008316885, 18353996.
21. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349. 10.1161/CIRCULATIONAHA.111.041418, 22007077.
22. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012, 59:265-276. 10.1016/j.jacc.2011.07.053, 22240132.
23. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228. 10.1161/01.RES.85.3.221, 10436164.
24. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007. 10.1056/NEJMoa043814, 16148285.
25. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609. 10.2337/dc10-0187, 2890368, 20357375.
26. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3. 10.1186/1475-2840-12-3, 3585887, 23286208.
27. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor. Improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes 2013, Sitagliptin: Circ J, [Epub ahead of print].
28. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 2012, 83:823-832. 10.1016/j.bcp.2011.11.028, 22172989.
29. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012, 11:92. 10.1186/1475-2840-11-92, 3471040, 22867630.